Bayer, Exscientia Part Ways On Artificial Intelligence Collaboration
Exscientia Plc (NASDAQ:EXAI) has ended its collaboration with Bayer AG (OTC: BAYRY) following the achievement of a drug discovery milestone. Exscientia will retain the…
Cassava Insiders Got A Lot Richer As Shares Rebound Following Refutation of Data Manipulation Claims
Journal of Prevention of Alzheimer’s Disease (JPAD) informed Cassava Sciences Inc (NASDAQ:SAVA) about no convincing evidence to support data manipulation allegations…
Novavax’s Covid-19 Vaccine Cleared For Use In New Zealanders Aged 12-17
New Zealand’s Medsafe has granted expanded provisional approval for Novavax Inc’s (NASDAQ:NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in adolescents aged 12 through 17.…
Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation
CureVac N.V. (NASDAQ:CVAC) and GSK plc (NYSE:GSK) have started a Phase 1 trial of the modified COVID-19 mRNA vaccine candidate, administered as a…
China-Based Jemincare Inks Prostate Cancer Drug Pact With Roche’s Genentech
After penning a deal with Orion in May for a non-opioid pain drug, Jemincare is back at the…
Astellas’ Menopause Drug Under FDA Review
The FDA accepted Astellas Pharma Inc’s (OTC:ALPMF) menopause treatment for approval five months after the therapy hit a speed bump in…
Arcturus’ COVID-19 Booster Shows Durability Against Omicron Variants
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) announced updated data from its ongoing ARCT-154 booster clinical trial. The new results demonstrate a broad…
89bio Shares Climb After Concluding Enrolment In Mid-Stage NASH Study
89bio (NASDAQ: ETNB) has completed enrollment in ENLIVEN, the Phase 2b trial of pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH).
AIM Immunotech Announces Commencement Of Phase 2 Study Of Ampligen For The Treatment Of Pancreatic Cancer
AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune